Recently, several postoperative nomograms for cancer-specific survival (CSS) after radical nephroureterectomy (RNU) were proposed, while they did not incorporate the same variables; meanwhile, many preoperative bloodbased parameters, which were recently reported to be related to survival, were not included in their models. In addition, no nomogram for overall survival (OS) was available to date.
INTRODUCTION AND OBJECTIVES:
Recently, several postoperative nomograms for cancer-specific survival (CSS) after radical nephroureterectomy (RNU) were proposed, while they did not incorporate the same variables; meanwhile, many preoperative bloodbased parameters, which were recently reported to be related to survival, were not included in their models. In addition, no nomogram for overall survival (OS) was available to date.
METHODS: The full data of 716 patients were available. The whole cohort was randomly divided into two cohorts: the training cohort for developing the nomograms (n [ 508) and the validation cohort for validating the models (n [ 208). Univariate and multivariate Cox proportional hazards regression models were used for establishing the prediction models. The discriminative accuracy of nomograms were measured by Harrell's concordance index (C-index). The clinical usefulness and net benefit of the predictive models were estimated and visualized by using Decision curve analyses (DCA).
RESULTS: The median follow-up time was 42.0 months (IQR: 18.0-76.0). For CSS, tumor size, grade and pT stage, lymph node metastasis, NLR, PLR and fibrinogen level were identified as independent risk factors in the final model; while tumor grade and pT stage, lymph node metastasis, PLR, Cys-C and fibrinogen level were identified as independent predictors for OS model. The proposed nomograms for OS and CSS were shown in Fig. 1A and 1B, respectively. The C-index for CSS prediction was 0.82 (95%CI: 0.79-0.85), and the OS nomogram model had an accuracy of 0.83 (95%CI: 0.80-0.86). The results of bootstrapping showed no deviation from the ideal. The calibration plots for the probability of CSS and OS at 3 or 5-year after RNU showed a favorable agreement between the prediction by the nomograms and actual observation. In the external validation cohort, the C-indexes of the nomograms for predicting CSS and OS were 0.79 (95%CI: 0.74-0.84) and 0.80 (95%CI: 0.75-0.85), respectively. As indicated by calibration plots, optimal agreement was observed between prediction and observation in the external cohort.
CONCLUSIONS: The nomograms developed and validated based on preoperative blood-based parameters were superior and more accurate than any single variable for predicting CSS and OS after RNU.
Source of Funding: This program was supported by the National key research and development program of China (Grant No. SQ2017YFSF090096), the Prostate Cancer Foundation Young Investigator Award 2013, the National Natural Science Foundation of China (Grant No. 81300627, 81370855, 81702536, 81770756 (cNþ) is an aggressive disease state with a high propensity for metastases and death. Current literature regarding the national practice patterns and outcomes for this patient population is limited. Our objective is to describe the current practice patterns and survival outcomes for treatment strategies in cNþM0 UTUC patients.
METHODS: 1,658 patients were identified in the National Cancer Database between 2004-2013 with cNþM0 UTUC. Patients were stratified into treatment groups. We compared baseline patient and tumor characteristics between groups, and completed a survival analysis using a multivariate Cox regression model accounting for all clinical variables associated with overall survival.
RESULTS: There were 1,658 patients in the final study population. Pre-operative chemotherapy was the least utilized treatment group, comprising 6.8% of the overall population, and was associated with the highest median overall survival (36 months; Adjuvant chemotherapy: 21 mo.; Chemotherapy only: 14 mo.; Surgery without perioperative chemotherapy: 10 mo.; No treatment: 5 mo.). On multivariate analysis, pre-operative chemotherapy was associated with improved median overall survival as compared to the adjuvant chemotherapy group ). There was no statistically significant difference in survival between the chemotherapy only and surgery only groups. 34.6% of patients in the pre-operative chemotherapy group achieved pN0 as compared to 10.3% of those who underwent surgery as initial therapy. Only 5.3% of patients in the surgery only group were coded in NCDB as having a documented contraindication to receipt of multi-agent chemotherapy.
CONCLUSIONS: Pre-operative chemotherapy was the least utilized treatment strategy in the management of cNþM0 UTUC but was associated with the highest median overall survival, with a 15 month survival advantage over adjuvant chemotherapy. There was no difference in survival between the chemotherapy only and surgery only groups. Overall these results suggest that initial chemotherapy is appropriate in this population unless contraindicated. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e721
